Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

Cancer cell - 12 Jun 2012

Jackson James G, Pant Vinod, Li Qin, Chang Leslie L, Quintás-Cardama Alfonso, Garza Daniel, Tavana Omid, Yang Peirong, Manshouri Taghi, Li Yi, El-Naggar Adel K, Lozano Guillermina

Abstract excerpt

Studies on the role of TP53 mutation in breast cancer response to chemotherapy are conflicting. Here, we show that, contrary to dogma, MMTV-Wnt1 mammary tumors with mutant p53 exhibited a superior clinical response compared to tumors with wild-type p53. Doxorubicin-treated p53 mutant tumors failed to arrest proliferation, leading to abnormal mitoses and cell death, whereas p53 wild-type tumors arrested, avoiding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Mammary Neoplasms, Experimental

Share to Mammary Tumor Virus, Mouse

Share to RNA Interference

Share to Tumor Burden

Share to Wnt1 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 22698404
DOI: 10.1016/j.ccr.2012.04.027
PMCID: PMC3376352

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.PMID 22698404Read ↗

p53 in breast cancer subtypes and new insights into response to chemotherapy.Semantic proximity Read ↗

Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatmentSemantic proximity Read ↗

p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.Semantic proximity Read ↗

Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma.Semantic proximity Read ↗

Triple-negative breast tumors are dependent on mutant p53 for growth and survival.Semantic proximity Read ↗

A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.Semantic proximity Read ↗

Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells.Semantic proximity Read ↗

Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancerSemantic proximity Read ↗

TP53 status and response to chemotherapy in breast cancer.Semantic proximity Read ↗

Polyploidy road to therapy‐induced cellular senescence and escapeSemantic proximity Read ↗

New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy.Semantic proximity Read ↗

A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.